Literature DB >> 26221843

Noninvasive theranostic imaging of HSV-TK/GCV suicide gene therapy in liver cancer by folate-targeted quantum dot-based liposomes.

Dan Shao1, Jing Li, Yue Pan, Xin Zhang, Xiao Zheng, Zheng Wang, Ming Zhang, Hong Zhang, Li Chen.   

Abstract

Theranostics is emerging as a popular strategy for cancer therapy; thanks to the development of nanotechnology. In this work, we have combined an HSV-TK/GCV suicide gene system and near-infrared quantum dots, as the former is quite effective in liver cancer treatment and the latter facilitates tumor imaging. A folate-modified theranostic liposome (FL/QD-TK) was developed, which is composed of an HSV-TK suicide gene covalently coupling with near-infrared fluorescent CdSeTe/ZnS core/shell quantum dots. The liver cancer-targeting and biosafety of FL/QD-TK were studied in vitro and in vivo. FL/QD-TK exhibited highly specific tumor imaging and strong inhibition of the folate receptor-overexpressed Bel-7402 mouse xenografts without systematic toxicity. This study may shed light on gene delivery and targeted cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26221843     DOI: 10.1039/c5bm00077g

Source DB:  PubMed          Journal:  Biomater Sci        ISSN: 2047-4830            Impact factor:   6.843


  15 in total

Review 1.  Methods for Intracellular Delivery of Quantum Dots.

Authors:  Sueden O Souza; Rafael B Lira; Cássia R A Cunha; Beate S Santos; Adriana Fontes; Goreti Pereira
Journal:  Top Curr Chem (Cham)       Date:  2021-01-05

Review 2.  Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities.

Authors:  Umme Ruman; Sharida Fakurazi; Mas Jaffri Masarudin; Mohd Zobir Hussein
Journal:  Int J Nanomedicine       Date:  2020-03-03

3.  Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery.

Authors:  Zhengzou Fang; Xinyuan Li; Zeyan Xu; Fengyi Du; Wendi Wang; Ruihua Shi; Daqing Gao
Journal:  Int J Nanomedicine       Date:  2019-07-30

4.  Targeted Inhibitory Effect of Nasopharyngeal Carcinoma Cells by Hre2.Grp78 Chimeric Promoter Regulating Fusion Gene TK/VP3.

Authors:  Jin-Yun Li; Wen-Xiao Huang; Jie Chen; Su-Ping Zhao; Yao-Yun Tang
Journal:  Technol Cancer Res Treat       Date:  2019 Jan-Dec

Review 5.  Nanobased Platforms for Diagnosis and Treatment of COVID-19: From Benchtop to Bedside.

Authors:  Elham Bidram; Yasaman Esmaeili; Abbas Amini; Rossella Sartorius; Franklin R Tay; Laleh Shariati; Pooyan Makvandi
Journal:  ACS Biomater Sci Eng       Date:  2021-05-12

6.  Cytotoxicity of various types of gold-mesoporous silica nanoparticles in human breast cancer cells.

Authors:  Guomu Liu; Qiongshu Li; Weihua Ni; Nannan Zhang; Xiao Zheng; Yingshuai Wang; Dan Shao; Guixiang Tai
Journal:  Int J Nanomedicine       Date:  2015-09-30

Review 7.  The Research and Applications of Quantum Dots as Nano-Carriers for Targeted Drug Delivery and Cancer Therapy.

Authors:  Mei-Xia Zhao; Bing-Jie Zhu
Journal:  Nanoscale Res Lett       Date:  2016-04-18       Impact factor: 4.703

8.  Self-assembled dual fluorescence nanoparticles for CD44-targeted delivery of anti-miR-27a in liver cancer theranostics.

Authors:  Xiao Zheng; Fan Zhang; Yawei Zhao; Jing Zhang; Jianati Dawulieti; Yue Pan; Lianzhi Cui; Madi Sun; Dan Shao; Mingqiang Li; Kan He; Ming Zhang; Jing Li; Li Chen
Journal:  Theranostics       Date:  2018-06-13       Impact factor: 11.556

Review 9.  Nanomaterial-based biosensors for detection of pathogenic virus.

Authors:  Ahad Mokhtarzadeh; Reza Eivazzadeh-Keihan; Paria Pashazadeh; Maryam Hejazi; Nasrin Gharaatifar; Mohammad Hasanzadeh; Behzad Baradaran; Miguel de la Guardia
Journal:  Trends Analyt Chem       Date:  2017-10-13       Impact factor: 12.296

Review 10.  Smart Stimuli-Responsive Liposomal Nanohybrid Systems: A Critical Review of Theranostic Behavior in Cancer.

Authors:  Jana K Alwattar; Amina T Mneimneh; Kawthar K Abla; Mohammed M Mehanna; Ahmed N Allam
Journal:  Pharmaceutics       Date:  2021-03-08       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.